Investing.com - Financial Markets Worldwide
🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Intellia Therapeutics Inc (38I)

Frankfurt
Symbol
Exchange
Currency
NTLANASDAQUSD
0JBULondonUSD
38ITradeGateEUR
38IFrankfurtEUR
Currency in EUR
13.4000
+0.4150(+3.20%)
Delayed Data
38I Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
12.575013.4000
52 wk Range
12.010031.7800
Key Statistics
Edit
Bid/Ask
12.36 / 12.48
Prev. Close
12.985
Open
12.575
Day's Range
12.575-13.4
52 wk Range
12.01-31.78
Volume
117
Average Volume (3m)
498
1-Year Change
-49.59%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
38I Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Buy
Price Target
59.7800
Upside
+361.2654%
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 14
13 analysts have revised their earnings upwards for the upcoming period
Unlock InvestingPro

Intellia Therapeutics Inc News & Analysis

Show more

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
526
Market
United States

Compare 38I to Peers and Sector

Metrics to compare
38I
Peers
Sector
Relationship
P/E Ratio
−2.6x−1.5x−0.6x
PEG Ratio
1.54−0.010.00
Price/Book
1.4x2.7x2.6x
Price / LTM Sales
32.1x5.8x3.2x
Upside (Analyst Target)
-157.4%45.4%
Fair Value Upside
Unlock20.7%7.7%Unlock

People Also Watch

Teradyne
123.35
TER
+1.98%
Recursion Pharmaceuticals
7.05
RXRX
+1.00%
Editas Medicine
1.68
EDIT
-11.38%
Beam
27.49
BEAM
-2.03%
Tempus AI
43.11
TEM
+2.66%

FAQ

What Is the Intellia Therapeutics Inc (38I) Stock Price Today?

The Intellia Therapeutics Inc stock price today is 13.40

What Stock Exchange Does Intellia Therapeutics Inc Trade On?

Intellia Therapeutics Inc is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for Intellia Therapeutics Inc?

The stock symbol for Intellia Therapeutics Inc is "38I."

What Is the Intellia Therapeutics Inc Market Cap?

As of today, Intellia Therapeutics Inc market cap is 1.28B.

What is Intellia Therapeutics Inc Earnings Per Share?

The Intellia Therapeutics Inc EPS is -5.44.

From a Technical Analysis Perspective, Is 38I a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.